Treatment of Kaposi's sarcoma by combination of actinomycin-D, vincristine and imidazole carboxamide (nsc-45388): results of a randomized clinical trial.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D003609:Dactinomycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014226:Triazenes / Q000627:therapeutic use*; D014454:Uganda; D014750:Vincristine / Q000627:therapeutic use*
D007093:Imidazoles; D014226:Triazenes; D003609:Dactinomycin; D014750:Vincristine; D003606:Dacarbazine